An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis

doi:10.25251/skin.4.supp.73

Keywords

Psoriasis, Tyrosine Kinase 2 Inhibitor, TYK2 Inhibitor, Oral, Efficacy

Abstract

Abstract not available.

References

1. Weigle N, McBane S. Am Fam Physician. 2013;87(9):626-633.

2. Puig L et al. Acta Derm Venereol. 2019;99(11):971-977.

3. Papp K et al. N Engl J Med. 2018;379(14):1313-1321.

Poster PDF

Published

Oct 27, 2020

DOI https://doi.org/10.25251/skin.4.supp.73

How to Cite

An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. (2020). SKIN The Journal of Cutaneous Medicine, 4(6), s73. https://doi.org/10.25251/skin.4.supp.73

Issue

Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

Section

Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

Jeffrey M. Sobell, Boni Elewski, Subhashis Banerjee, Eugene Balagula, Thomas Scharnitz, Victoria Berger, Kim Hoyt, Paul Yamauchi, Miriam Bettencourt, Michael C. Cameron, Mark Lebwohl, Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
K Gordon, K Papp, M Gooderman, D Thaci, P Foley, A Morita, S Kundu, R Kisa, A Napoli, S Banerjee, Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher EM Griffiths, Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Bruce Strober, Howard Sofen, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew Alexis, Diamant Thaçi, Andrew Blauvelt, Mark Lebwohl, Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Diamant Thaçi, Mark Lebwohl, Richard B. Warren, Leon Kircik, Subhashis Banerjee, Andrew Napoli, Renata M. Kisa, Misti Linaberry, Kim Hoyt, Andrew Blauvelt, Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt, Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Jerry Bagel, April Armstrong, Richard Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Griffiths, Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov, Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Victoria P. Werth, Marilyn Pike, Joan T. Merrill, Eric Morand, Ronald van Vollenhoven, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee, Shalabh Singhal, Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Joe Merola, Howard Sofen, Diamant Thaci, Carle Paul, Shinichi Imafuku, Subhashis Banerjee, April Armstrong , Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 > >>

You may also start an advanced similarity search for this article.

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles